Volume 22, Number 3—March 2016
CME ACTIVITY - Synopsis
Patient Report and Review of Rapidly Growing Mycobacterial Infection after Cardiac Device Implantation
Table 2
Clinical and demographic information for published cases of cardiac device infections due to rapidly growing mycobacteria*
Year (ref) | Age, y/ sex | Organism | Type | Onset† | Bacteremia/ lead infection‡ | IE§ | Macrolide resistant | Device removed | Antimicrobial drug therapy | Outcome |
---|---|---|---|---|---|---|---|---|---|---|
Mycobacterium fortuitum group |
||||||||||
1998 (6) | 74/M | M. fortuitum + M. chelonae | PPM | 13 d | NR/NR | NR | NR | Yes | FQ + AG × 4 wk | Cured |
2005 (9) | 62/F | M. fortuitum | PPM | 6 mo | Yes/yes | Yes | No | Yes | CLR + CIP × 4 wk, DOX + CIP × 24 wk | Cured |
2005 (10) | 74/M | M. peregrinum | ICD | 6 wk | Yes/NR | NR | No | Yes | CLR + CIP × 6 wk | Cured |
2005 (8) | 72/M | M. fortuitum | PPM | 2 wk | No/NR | No | Yes | Yes | CIP + AG × 2 wk, CIP × 6 mo | Cured |
61/M | M. fortuitum | ICD | 17 mo | No/yes | No | Yes | Yes | LVX × >1 y¶ | Cured | |
2006 (11) | 80/M | M. fortuitum | PPM | 18 d | Yes/NA | No | No | No | CLR + CIP × 6 wk | Cured |
2007 (13) | 84/F | M. fortuitum | PPM | 1 mo | No/no | No | Yes | Yes | LVX × 3 mo | Cured |
2007 (15) | 78/F | M. fortuitum | PPM | 3 mo | Yes/yes | No | NR | Yes | CLR + LVX + LZD × 2 wk, CLR + LVX × 6 mo | Cured |
2007 (16) | 78/F | M. fortuitum | PPM | <4 mo | Yes/NR | NR | NR | Yes | CLR + LVX + LZD × 2 wk, CLR + LVX × 22 wk | Cured |
77/F | M. mageritense | PPM | 3 wk | NR/NA | NR | NR | No | FQ × 6 mo | Cured | |
2009 (18) | 15/F | M. fortuitum | PPM | 7 wk | Yes/yes | No | No | Yes | CLR + CIP × 6 mo | Cured |
2010 (20) | 78/M | M. fortuitum | PPM | NR | Yes/NR | NR | NR | Yes | CLR + CIP × 26 wk | Cured |
2012 (23) | 43/M | M. fortuitum | ICD | 4 y | Yes/yes | Yes | No | Yes | CLR + CIP + AG | Died |
2012 (22) | 75/M | M. peregrinum | PPM | 1 y | Yes/yes | No | NR | Yes | CLR + CIP × mo | Cured |
2015# |
60/M |
M. fortuitum group |
ICD |
6 wk |
Yes/no |
No |
Yes |
Yes |
CLR + CIP + FOX |
Died |
M. abscessus complex |
||||||||||
1998 (5) | 68/M | M. abscessus | PPM | 19 y | NR/yes | NR | No | Yes | CLR + AG + FOX × 5 wk | Died |
2005 (7) | 53/M | M. abscessus | ICD | 2 wk | NR/NR | NR | Yes | Yes | CLR × 24 wk | Cured |
2007 (14) |
43/F |
M. massiliense |
PPM |
11 mo |
NR/yes |
NR |
No |
Yes |
CLR × 6 mo |
Cured |
M. smegmatis complex |
||||||||||
2006 (12) | 86/M | M. goodii | PPM | 16 d | Yes/NR | NR | NR | Yes | Multiple, ending with MIN + AG × 2 wk | Cured |
2008 (17) | 85/M | M. goodii | ICD | <7 d | No/NR | No | NR | Yes | TMP/SXT × 8 wk | Cured |
2009 (19) |
23/M |
M. goodii |
PPM |
8 d |
No/NA |
No |
Yes |
No |
DOX + FQ × 6 mo |
Cured |
M. chelonae complex |
||||||||||
2014 (24) |
63/M |
M. chelonae |
PPM |
NR |
No/yes |
Yes |
NR |
Yes |
CLR + LVX + AG × >2 mo |
Cured |
Ungrouped rapidly growing species |
||||||||||
2011 (21) | 73/M | M. phlei | ICD | 1 mo | No/NR | NR | No | Yes | SXT + DOX × 12 mo | Cured |
*AG, aminoglycoside; CIP, ciprofloxacin; CLR, clarithromycin; DOX, doxycycline; FOX, cefoxitin; FQ, fluoroquinolone other than CIP or LVX; ICD, implantable cardioverter-defibrillator; IE, infective endocarditis; LVX, levofloxacin; LZD, linezolid; MIN, minocycline; NA, not available; NR, not reported; PPM, permanent pacemaker; ref, reference; TMP/SXT, trimethoprim/sulfamethoxazole.
†Time since most recent device manipulation.
‡Defined as positive lead culture, acid fast stain, or presumptive diagnosis on the basis of imaging or operative findings.
§Transthoracic or transesophageal echocardiographic findings as defined by the Duke criteria (25).
¶No end date for therapy was specified, but patient had at least 1 year of treatment.
#The patient described in this article.
References
- Uslan DZ, Sohail MR, St Sauver JL, Friedman PA, Hayes DL, Stoner SM, Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. Arch Intern Med. 2007;167:669–75. DOIPubMedGoogle Scholar
- Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. CLSI Document M24–A2. Wayne (PA); 2011.
- Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev. 2002;15:716–46. DOIPubMedGoogle Scholar
- von Graevenitz A, Punter-Streit V. Failure to recognize rapidly growing mycobacteria in a proficiency testing sample without specific request—a wider diagnostic problem? Eur J Epidemiol. 1998;14:519–20. DOIPubMedGoogle Scholar
- Amin M, Gross J, Andrews C, Furman S. Pacemaker infection with Mycobacterium avium complex. Pacing and clinical electrophysiology. Pacing Clin Electrophysiol. 1991;14:152–4. DOIPubMedGoogle Scholar
- Katona P, Wiener I, Saxena N. Mycobacterium avium–intracellulare infection of an automatic implantable cardioverter defibrillator. Am Heart J. 1992;124:1380–1. DOIPubMedGoogle Scholar
- Doherty JG, Rankin R, Kerr F. Miliary tuberculosis presenting as infection of a pacemaker pulse-generator pocket. Scott Med J. 1996;41:20–1.PubMedGoogle Scholar
- Hellwig T, Ou P, Offredo C, Stephany D, Bonnet D, Sidi D. Unusual chronic pacemaker infection by Mycobacterium tuberculosis in a pediatric patient. J Thorac Cardiovasc Surg. 2005;130:937–8. DOIPubMedGoogle Scholar
- Kestler M, Reves R, Belknap R. Pacemaker wire infection with Mycobacterium tuberculosis: a case report and literature review. Int J Tuberc Lung Dis. 2009;13:272–4.PubMedGoogle Scholar
- Luckie M, Zaidi A, Woodhead M, Garratt C. Mycobacterium tuberculosis causing infection of an implantable biventricular defibrillator. Indian J Tuberc. 2010;57:213–5.PubMedGoogle Scholar
- Stone DR, Estes NA III, Klempner MS. Mycobacterium bovis infection of an implantable defibrillator following intravesical therapy with bacille Calmette-Guerin. Clin Infect Dis. 1993;16:825–6. DOIPubMedGoogle Scholar
- Kumar A, Agrawal T. A study of unusual pacemaker infection by mycobacterium tuberculosis in Indian patients. Indian Pacing Electrophysiol J. 2014;14:291–6.PubMedGoogle Scholar
- Wallace RJ Jr, Musser JM, Hull SI, Silcox VA, Steele LC, Forrester GD, Diversity and sources of rapidly growing mycobacteria associated with infections following cardiac surgery. J Infect Dis. 1989;159:708–16. DOIPubMedGoogle Scholar
- Wallace RJ Jr, Steele LC, Labidi A, Silcox VA. Heterogeneity among isolates of rapidly growing mycobacteria responsible for infections following augmentation mammaplasty despite case clustering in Texas and other southern coastal states. J Infect Dis. 1989;160:281–8. DOIPubMedGoogle Scholar
- Uslan DZ, Kowalski TJ, Wengenack NL, Virk A, Wilson JW. Skin and soft tissue infections due to rapidly growing mycobacteria: comparison of clinical features, treatment, and susceptibility. Arch Dermatol. 2006;142:1287–92. DOIPubMedGoogle Scholar
- El Helou G, Hachem R, Viola GM, El Zakhem A, Chaftari AM, Jiang Y, Management of rapidly growing mycobacterial bacteremia in cancer patients. Clin Infect Dis. 2013;56:843–6. DOIPubMedGoogle Scholar
- Nash KA, Zhang Y, Brown-Elliott BA, Wallace RJ Jr. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Antimicrob Chemother. 2005;55:170–7. DOIPubMedGoogle Scholar
- Schembri S, Williamson PA, Short PM, Singanayagam A, Akram A, Taylor J, Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ. 2013;346:f1235. DOIPubMedGoogle Scholar
- Lapi F, Wilchesky M, Kezouh A, Benisty JI, Ernst P, Suissa S. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis. 2012;55:1457–65. DOIPubMedGoogle Scholar